2024 Global Cancer Diagnostics Market: US, Europe, Japan--Supplier Shares and Strategies, Volume and Sales Segment Forecasts--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

August 2024 | - | ID: 25085304BE35EN
Venture Planning Group

Abstracts

This new report from LeadingMarketResearch.com is based on a new study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Asia; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.
Geographic Coverage
France, Germany, Italy, Japan, Spain, UK, USA
Worldwide Market Overview

• Five-year test volume and sales projections by country.
• Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
• Estimated universe of laboratories performing cancer diagnostic testing by country.
• Cancer statistics, etiology and recent developments in the U.S., Europe, and Asia.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

• Oncogenes
• Biochemical Markers
• Growth Factors
• Colony Stimulating Factors
• Hormones
• Immunohistochemical Stains
• Lymphokines

Supplier Shares, Sales and Volume Forecasts

• Sales and market shares of major cancer diagnostic product suppliers by individual test and country.
• Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:

? Hospitals
? Commercial/Private Laboratories
? Physician Offices/Group Practices
? Cancer Clinics
? Ambulatory Care Centers
Instrumentation Review

• Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

• Assessment of latest technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies.
• Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

• Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
• The companies analyzed in the report include:
• Abbott
• Affymetrix
• Beckman Coulter/Danaher
• Becton Dickinson
• bioMerieux
• Bio-Rad
• Cepheid
• Diamedix
• DiaSorin
• Eiken Chemical
• Elitech Group
• Enzo Biochem
• Fujirebio
• Grifols
• GSK Biologicals
• Hologic
• Leica Biosystems
• Lonza
• Ortho-Clinical Diagnostics
• PerkinElmer
• Qiagen
• Roche
• Scienion
• Sequenom
• SeraCare
• Siemens Healthineers
• Takara Bio
• Thermo Fisher
• Wako

Contains 1,200 pages and 450 tables

Contents

I. Introduction
II. Market Overview
III. Major Product Development Opportunities
IV. Design Criteria for Decentralized Testing Products
V. Alternative Market Penetration Strategies
VI. Potential Market Entry Barriers and Risks
VII. Major Current and Emerging Cancer Diagnostic Tests

1. INTRODUCTION

2. CANCER DIAGNOSTIC CLASSIFICATION

3. ACTH

4. ALPHA-FETOPROTEIN (AFP)

5. BETA-2 MICROGLOBULIN

6. CA 15-3/27.29

7. CA 19-9

8. CA-125

9. CALCITONIN

10. CARCINOEMBRIONIC ANTIGEN (CEA)

11. ESTROGEN AND PROGESTERONE RECEPTORS

12. FERRITIN

13. GASTRIN

14. HUMAN CHORIONIC GONADOTROPIN (HCG)

15. INSULIN

16. NSE

17. OCCULT BLOOD

18. PAP SMEAR/HPV

19. PROSTATIC ACID PHOSPHATASE (PAP)

20. PROSTATE-SPECIFIC ANTIGEN (PSA)

21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)

22. T AND B LYMPHOCYTES

23. TDT

24. THYROGLOBULIN

25. TISSUE POLYPEPTIDE ANTIGEN (TPA)

26. BIOCHEMICAL CANCER DIAGNOSTICS

27. ONCOGENES

- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
Table of Contents (continued)
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src and others

28. POLYPEPTIDE GROWTH FACTORS

- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR
- Nerve Growth Factor (NGF)
- Epidermal Growth Factor (EGF)
- Ornithine Decarboxylase
- Transferrin
- Transforming Growth Factor-Alpha

29. ECTOPIC HORMONES

30. COLONY STIMULATING FACTORS

31. LYMPHOKINES

- Alpha-Interferon
- B Cell Growth Factors
- B Cell Growth Factor (BCGF)
- Gamma-Interferon
- Interleukin-1 (IL-1)
- Macrophage Activating Factor

32. IMMUNOHISTOCHEMICAL STAINS

33. EMERGING CANCER DIAGNOSTICS

- N-Acetylglucosamine
- Actin
- Alpha-Actin
- Antineuronal Antibodies
- 7B2
- B72.3
- Bax